Novacyt S.A. (EPA:ALNOV)
0.3900
+0.0040 (1.04%)
Jun 23, 2026, 5:35 PM CET
Novacyt Revenue
In the year 2025, Novacyt had annual revenue of 20.03M GBP with 2.03% growth. Novacyt had revenue of 10.24M in the half year ending December 31, 2025, with 40.57% growth.
Revenue
20.03M GBP
Revenue Growth
+2.03%
P/S Ratio
1.23
Revenue / Employee
92.73K GBP
Employees
216
Market Cap
28.26M EUR
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.03M | 399.00K | 2.03% |
| Dec 31, 2024 | 19.63M | 9.01M | 84.82% |
| Dec 31, 2023 | 10.62M | -10.42M | -49.52% |
| Dec 31, 2022 | 21.04M | -71.56M | -77.28% |
| Dec 31, 2021 | 92.60M | -184.60M | -66.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guerbet | 798.67M |
| Biosynex | 95.19M |
| Diagnostic Medical Systems | 52.86M |
| Median Technologies | 23.47M |
| Implanet | 12.47M |
| Bluelinea Société Anonyme | 11.12M |
| Mauna Kea Technologies | 8.91M |
| SpineGuard | 3.76M |
Novacyt News
- 7 weeks ago - Novacyt Earnings Call Transcript: H2 2025 - Transcripts
- 7 weeks ago - Novacyt Annual report: H2 2025 - Filings
- 7 weeks ago - Novacyt Annual report: H2 2025 - Filings
- 2 months ago - Novacyt Transcript: Status update - Transcripts
- 5 months ago - Novacyt Earnings release: H2 2025 - Filings
- 9 months ago - Novacyt Earnings release: H1 2025 - Filings
- 9 months ago - Novacyt Quarterly report: H1 2025 - Filings
- 11 months ago - Novacyt Quarterly report: Q2 2025 - Filings